Mesh Bio, a Singaporean health-tech startup, has raised US$1.8 million in a seed funding round, led by deep-tech investor Elev8.vc and SEEDS capital.
Wealth management firm Citrine Capital as well as Singaporean VC firm Tael Partners also joined the round.
Mesh Bio intends to use the capital to accelerate the rollout of its solution, DARA, for healthcare providers in Southeast Asia and Hong Kong. The funds will also support the startup’s clinical partnerships and collaborations.
Mesh Bio intends to expand its solution further across Southeast Asia and Hong Kong.